hero image

CORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London

September 10, 2015 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--First paragraph, second sentence of release should read: The webcast will be live on Friday, September 18, 2015 at 10:40 a.m. BST (5:40 a.m. ET.)

The corrected release reads:

BIOGEN TO PRESENT AT BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE LONDON

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at Bank of America Merrill Lynch Global Healthcare Conference London. The webcast will be live on Friday, September 18, 2015 at 10:40 a.m. BST (5:40 a.m. ET.) To access the live webcast, please visit Biogen’s Investors section at www.biogen.com. An archived version of the webcast will be available for 14 days following the presentation.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.

 

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

thumb
May 14, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the

thumb
May 2, 2024
Biogen Reports Progress on Corporate Responsibility Priorities

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s